Key Drivers
- Strong Liquidity
- No Revenue
- Cash Burn
AIAI Summary
AMLX is no longer best viewed as a distressed biotech but as a well-funded, catalyst-driven binary bet on avexitide, with Q3 Phase 3 LUCIDITY data likely to determine whether the stock re-rates sharply or stays trapped under bearish tape despite strong liquidity and runway.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Cash Burn
AMLX has a strong balance sheet and very low leverage, but zero revenue, ongoing losses, and heavy cash burn keep the investment case high-risk despite near-term liquidity.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Lower lows
- •Support test
AMLX remains in a clear downtrend over the last month, with lower highs/lower lows and resistance at $14.5-$15.0, so bulls need the $13.3-$13.6 support to hold for any bounce.
Sharp drop from $18.36 to $13.29 with persistent selling pressure
Sentiment & News
Key News Insights:
- •Avexitide progress
- •Expanded access
- •AMX0035 validation
Amylyx is advancing avexitide toward a Q3 Phase 3 readout while expanding access in post-bariatric hypoglycemia and validating AMX0035 with new peer-reviewed data.
The updates are modestly positive for Amylyx, as they strengthen the near-term clinical catalyst path and reinforce confidence in its pipeline execution
Similar Companies in Healthcare
Other companies in the same sector with AI ratings